Arcturus Therapeutics

Arcturus Therapeutics San Diego Office Headquarters

Dr. Michael R. HodgesDr. Michael R. HodgesDr. Michael R. Hodges has 24 years of biopharmaceutical development experience in both large pharmaceutical and biotechnology companies across a broad range of therapeutic areas, including infectious disease, oncology, respiratory and dyslipidemia. He is currently CMO at Amplyx Pharmaceuticals and recently served as the Vice President of Drug Development and Chief Medical Officer for Santaris A/S, an RNA therapeutic platform company developing drugs for cancer, infectious diseases and metabolic diseases. Santaris was acquired by Hoffmann-La Roche AG in September 2014. Prior to Santaris, Michael was the Chief Medical Officer for Altair Inc., a respiratory RNA therapeutics platform company, developing inhaled drugs for asthma and other pulmonary inflammatory diseases. He served in Pfizer Global Research and Development in Sandwich UK, Groton CT USA, New London CT USA and La Jolla CA USA, for 17 years and his career has included working on the development programs for the following commercial products: Vfend®, Eraxis®, Diflucan®, Zithromax®, Tarceva®, Inlyta® and Viagra®. Before joining the pharmaceutical industry, Michael practiced internal medicine in the United Kingdom. Michael received his undergraduate degree in Pharmacology from Kings College, and medical degree at the Westminster Medical School, University of London, UK.

Dr. Drew WeissmanDr. Drew WeissmanDr. Weissman, is a professor of Medicine at the Perelman School of Medicine, University of Pennsylvania with over 100 publications and patents. He received his graduate degrees from Boston University School of Medicine. Dr. Weissman co-discovered the ability of modified nucleosides in RNA to suppress activation of innate immune sensors and increase the translation of mRNA containing certain modified nucleosides. Dr. Weissman's laboratory focuses on the study of RNA and innate immune system biology and the application of these findings to vaccine research, protein therapeutics, and gene therapy. He is also an Attending Physician at the Philadelphia Veterans Administration Medical Center, a member of The American Association of Immunologists, and a member of the American Federation for Clinical Research.

Dr. Pad ChivukulaDr. Pad ChivukulaDr. Chivukula previously served as Chief Scientific Officer and Chief Operating Officer of Arcturus Therapeutics Ltd. and was formerly on Arcturus’ Board since March 2013. Prior to Arcturus, from June 2008 until February 2013, Dr. Chivukula was employed by Nitto Denko Corporation, where his titles included Group Leader and Chief Scientist, and where he led the polymeric RNAi research department. Dr. Chivukula's background includes over 15 years of experience in drug delivery and therapeutic drug development at Nitto Denko Corporation and the University of Utah. Dr. Chivukula has a Ph.D. in Pharmaceutical Chemistry from the University of Utah where he specialized in lipid-mediated delivery systems and technology.

Dr. Michael R. Hodges has 24 years of biopharmaceutical development experience in both large pharmaceutical and biotechnology companies across a broad range of therapeutic areas, including infectious disease, oncology, respiratory and dyslipidemia.

Dr. Weissman, is a professor of Medicine at the Perelman School of Medicine, University of Pennsylvania with over 100 publications and patents.

News & Events